Últimas noticias sobre BioCardia (NASDAQ:BCDA) Bolsa

BioCardia

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

BioCardia Inc

Billionaire investor Mark Cuban has urged GenZ youth to upscale themselves by learning more about artificial intelligence. As growing AI applications have been disrupting business, here is a list of AI-linked investment opportunities that investors could consider to increase their exposure.
What Happened: During an <a href="https://www.youtube.com/watch?v=vkJfCMycJRk">interaction</a> at South by Southwest or SXSW festival in Austin, Texas, Cuban said that it was pivotal to learn about AI to integrate it into business.
Addressing the entrepreneurship-oriented youth, Cuban said, &#8220;I would spend every waking minute learning about AI,&#8221; when asked about advice for the next generation of business leaders.
He also used his own Instagram and TikTok feed as an example, stating that it consisted of AI hacks because of the rapid technological changes and AI adoption.
&#8220;It&#8217;s one thing to have a business and how you integrate AI. But if you&#8217;re just getting started, as you learn these things, it&#8217;s so much easier to start,&#8221; he said.
&#8220;Whether you use Perplexity, Anthropic Claude, ChatGPT, Gemini. It doesn&#8217;t matter, right?&#8221; he said rhetorically stating that AI tools can &#8220;spider everything&#8221; from writing emails to doing sales calls.
However he added that most people won&#8217;t leverage the capabilities of AI, &#8220;But those people who put in the time are going to crush it,&#8221; he said.
See Also: <a href="https://www.benzinga.com/25/03/44350479/warren-buffett-plans-to-sell-his-real-estate-brokerage-but-its-not-a-bet-against-us-home-prices-says-analyst-as-fed-expects-to-keep-rates-unchanged" target="_blank" rel="noreferrer noopener">Warren Buffett Plans To Sell His Real Estate Brokerage, But It's ‘Not… A Bet Against US Home Prices,' Says Analyst As Fed Expects To Keep Rates Unchanged</a>
Why It Matters: The AI race has been intensifying worldwide. The popularity of Chinese AI startup DeepSeek triggered a selloff in AI-linked stocks and major AI chipmaker Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in mid-January.
While companies worldwide are finding a way for AI training and inferencing without using Nvidia&#8217;s advanced chips, the South China Morning Post <a href="https://www.scmp.com/tech/tech-war/article/3302516/chip-war-chinese-start-aims-break-nvidias-grip-ai-new-model-framework">reported</a> on Sunday that a Tsinghua University-linked team introduced an AI framework that can work on Chinese-made chips. 
Qingcheng.AI and Tsinghua University unveiled Chitu, an LLM inference framework for Chinese chips, challenging Nvidia&#8217;s GPUs by supporting models like DeepSeek-R1.
Thus, as AI gains more prominence and global firms strive to improve efficiency, here is a list of AI-exposed exchange-traded funds listed in the U.S. that investors could consider in the long term.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>ETF Name</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>iShares US Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>)</td>
<td>-8.74%</td>
<td>9.36%</td>
</tr>
<tr>
<td>Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>)</td>
<td>-9.41%</td>
<td>9.04%</td>
</tr>
<tr>
<td>First Trust Dow Jones Internet Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDN#NYSE">FDN</a>)</td>
<td>4.21%</td>
<td>13.93%</td>
</tr>
<tr>
<td>iShares Expanded Tech Sector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGM#NYSE">IGM</a>)</td>
<td>-7.70%</td>
<td>10.80%</td>
</tr>
<tr>
<td>iShares Global Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXN#NYSE">IXN</a>)</td>
<td>-7.21%</td>
<td>6.19%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Monday. The SPY was down 0.30% to $561.12, and the QQQ also declined 0.17% to $478.85, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
SPY closed 2.07% higher at $562.81 and QQQ rose 2.42% to $479.66 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44353578/safe-haven-amidst-volatility-gold-tops-3000-as-market-corrects-but-it-tends-to-see-painful-drawdowns-after-period">Safe Haven Amidst Volatility? Gold Tops $3000 As Market Corrects But It Tends To See &#8216;Painful Drawdowns After Periods Of Sharp Gains,&#8217; Says Expert</a></li>
</ul>
Photo courtesy: Shutterstock

News

Markets

Tech

First Trust Dow Jones Internet Index Fund

FTEC

iShares Trust S&P Global Information Technology Sector Index Fund

iShares Dow Jones US Technology Sector Index Fund

NVDA

Mark Cuban Advises GenZ To 'Spend Every Waking Minute Learning About AI:' Here's A List Of AI Investment Opportunities For Long Term

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/14/final-trades-uber-nrg-energy-franco-nevada-corp-and-meta.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) is sitting right on top of its 200-day and its <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">50-day moving averages</a>.
Supporting his view, Truist Securities analyst Youssef Squali, on March 6, maintained Uber Technologies with a Buy rating and raised the price target from $90 to $92.
Rob Sechan of NewEdge Wealth named NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) as his final trade.
NRG Energy, on March 12, entered into a definitive agreement to acquire six power generation facilities from Rockland Capital, LLC for $560 million.
 Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Amy Raskin of Chevy Chase Trust picked Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>).
On the earnings front, Franco-Nevada, on March 10, reported fourth-quarter results. Revenue rose 6% year over year (+30% Y/Y excluding Cobre Panama) to $321.0 million, beating the consensus of $305.85 million. The company saw strong production from Candelaria, new assets, and benefiting from record gold prices.
Stephen Weiss of Short Hills Capital Partners named Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) as his final trade.
President Donald Trump has indicated that Meta Platforms could invest up to $60 billion in the United States by the end of the year.
Price Action:
<ul>
<li>Uber shares gained 2.9% to close at $71.55 on Friday.</li>
<li>NRG Energy rose 4.9% to settle at $95.39 during Friday's session.</li>
<li>Franco-Nevada rose 2.1% to close at $153.35 on Friday.</li>
<li>Meta shares gained 3% to close at $607.60 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march">Top 3 Materials Stocks That May Collapse In March</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

Trading Ideas

UBER

Uber, Meta, NRG Energy And A Basic Materials Stock On CNBC's 'Final Trades'

Inspired Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.24 by 33.33 percent. This is a 5.88 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $83.00 million which beat the analyst consensus estimate of $80.69 million by 2.86 percent. This is a 2.22 percent increase over sales of $81.20 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

INSE

Inspired Entertainment Q4 2024 Adj EPS $0.16 Misses $0.24 Estimate, Sales $83.00M Beat $80.69M Estimate

Leerink Partners analyst Faisal Khurshid initiates coverage on Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Market Perform rating and announces Price Target of $16.

Price Target

Initiation

Analyst Ratings

NRIX

Leerink Partners Initiates Coverage On Nurix Therapeutics with Market Perform Rating, Announces Price Target of $16

Warren Buffett-backed Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) is reportedly contemplating establishing a third assembly plant in Germany.
What Happened: According to a report by Reuters, BYD is looking to expand its manufacturing footprint in Europe and is considering Germany for its third plant. This move comes after Germany, Europe&#8217;s largest economy, opposed EU tariffs on Chinese-made electric vehicles last year.
The company is planning the third plant to expand its manufacturing footprint in Europe to boost sales of its affordable vehicles and compete with European rivals. With this, the company aims to circumvent import tariffs imposed by the EU on China-made EVs in the previous year.
Stella Li, BYD&#8217;s executive vice president, previously mentioned the possibility of a third European facility in an interview with Automobilwoche. While Hungary and Turkey are already in the works, Germany is a leading candidate for the new plant.
Also Read:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44299887/tsla-stock-may-see-a-significant-upswing-says-jim-cramer-should-be-ready-to-rally-maybe-furiously"> TSLA Stock May See A Significant Upswing, Says Jim Cramer: &#8216;Should Be Ready To Rally, Maybe Furiously&#8217;</a>
However, the decision is under scrutiny due to Germany&#8217;s high labor and energy costs, as well as low productivity and flexibility. The report, citing a source who wished to remain anonymous, noted that BYD is also considering Western Europe to enhance brand recognition and acceptance as a local manufacturer.
Why It Matters: The potential establishment of a new plant in Germany is part of <a href="https://www.benzinga.com/markets/penny-stocks/24/07/39690741/byd-has-its-eyes-set-on-conquering-europe">BYD&#8217;s aggressive expansion strategy</a> in Europe. The company has already made significant strides by entering the Greek market with its popular Atto 3 and Seal EV models.
BYD is adhering to Beijing&#8217;s directive to avoid investing in countries that supported the EU tariffs, excluding some EU nations like Italy and France from consideration. The final decision will depend on BYD&#8217;s sales performance in Europe and the capacity utilization of its Hungarian and Turkish plants.
In July 2024, BYD announced a $1 billion factory in Turkey. This facility is expected to produce 150,000 EVs annually, further solidifying BYD&#8217;s foothold in the region.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44295619/epa-targets-bidens-climate-policies-starts-process-to-reverse-passenger-vehicle-truck-emission-rules">EPA Moves To Overturn Biden-Era Climate Policies, Starts Process To Reverse Passenger Vehicle, Truck Emission Rules</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Global

BYDDF

BYDDY

Warren Buffett-Backed BYD Eyes Germany For Third European Plant Amid Tariff Concerns: Report

Leerink Partners analyst Faisal Khurshid initiates coverage on Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) with a Outperform rating and announces Price Target of $4.

STTK

Leerink Partners Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $4

At first glance, there doesn't seem to be anything that can stop the<a href="https://www.benzinga.com/government/regulations/25/03/44308014/gold-hits-record-highs-as-trade-war-fears-fuel-safe-haven-demand-mining-stocks-soar"> stratospheric ascent of gold</a>. Recently, the precious metal hit a fresh record as investors clamored for the perceived safety that the hard asset provides. Escalating fears tied to a potentially<a href="https://www.benzinga.com/topic/tariffs"> ugly trade war and economic uncertainty</a> have contributed to gold's cynical bull market.
Notably, the benchmark SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) has already gained almost 14% of market value since the beginning of the year. Over the past 52 weeks, the gold-centric exchange-traded fund returned almost 38%. Not surprisingly, funds tied to the precious metal have<a href="https://www.benzinga.com/etfs/specialty-etfs/25/03/44335436/gold-etfs-shine-as-spot-price-tops-3000-during-safe-haven-demand"> witnessed significant money inflows</a>. Nevertheless, the underlying mining complex has not kept pace.
All other things being equal, a rising gold price should be positive for gold miners. However, mining enterprises are first and foremost businesses, and businesses struggle with outside factors, such as<a href="https://www.benzinga.com/news/global/25/02/43618203/gold-nears-3000-but-miners-struggle-as-rising-costs-squeeze-profits"> cost overruns and labor shortages</a>. Of course, the speculation is that eventually, the<a href="https://www.benzinga.com/news/large-cap/25/01/43137560/golds-blowout-rally-puts-spotlight-on-miners-will-they-finally-catch-up"> mining complex may catch up to the underlying asset</a>.
Indeed, some high-profile investors have already<a href="https://www.benzinga.com/trading-ideas/movers/25/03/44331708/billionaire-hedge-funder-adds-mining-stocks-before-gold-makes-record-highs-gold-will-go-up-paulson-says"> stacked their portfolios with promising gold miners</a>. Fundamentally, the reasoning is that economic uncertainty may continue to incentivize institutional demand. If so, the yellow metal may continue its northward trek, potentially eventually catapulting the mining industry.
Nevertheless, not everyone is convinced about the compelling narrative of gold producers, particularly those in the more speculative junior category. Primarily, it's important to realize that central banks are buying gold, not gold stocks. What may be good for the metal itself might not translate downwind to every miner.
Moreover, retail investors themselves have preferred to stick with the actual commodity rather than deal with the vagaries of individual mining enterprises. Combined with the<a href="https://www.benzinga.com/news/25/01/42781668/trump-administration-will-be-an-unpredictability-machine-economists-warn-maganomics-could-hinder-lon"> unpredictability of the Trump administration</a>, gold's flashy rise to prominence could just as easily be cut short due to an unexpected policy pivot.
The Direxion ETFs: With so many ways the gold narrative can play out, traders interested in betting on both sides of the fence can do so with Direxion's junior-miner-specific ETFs. For the optimists, the Direxion Daily Junior Gold Miners Index Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNUG#NYSE">JNUG</a>) could be a relevant idea. On the other hand, pessimists can acquire units of the Direxion Daily Junior Gold Miners Index Bear 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JDST#NYSE">JDST</a>).
Both ETFs seek the daily investment results of 200% (or 200% of the inverse performance) of the MVIS Global Junior Gold Miners Index. Mainly, the purpose behind these leveraged ETFs is convenience. Rather than engage the options market – which can incur significant complexities – everyday investors have easy access to leveraged or inverse trading opportunities.
Direxion ETFs are functionally like any other publicly traded asset. Investors buy shares (or technically units) of these funds, in the hopes that they rise in value. This directional speculation applies to the inverse funds as well. For example, if JDST rises, this suggests that the underlying junior miner index was volatile.
Although the functionality of these Direxion funds is straightforward, prospective investors should realize that leveraged and inverse ETFs should only be held for no more than one day. Otherwise, the cumulative compounding of leverage could create unfavorable performance distortions between the ETF holding and the underlying index.
The JNUG ETF: As one might expect, the Direxion Daily Junior Gold Miners bull fund is off to a blistering start, gaining almost 58% since the beginning of the year.
<ul>
<li>JNUG has been on a tear recently, gaining nearly 13% in the trailing month. With this move, the leveraged fund is decisively above its 50- and 200-day moving averages.</li>
<li>Looking at a long-term view, it's possible that JNUG is charting a rounding bottom formation. If so, the bulls could be looking to spart a significant move higher.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeWd8M84ZT8SJI1kxcAnMXvmWTiCHOxGW9AMoYX0pNWMf9R9Qbfia1hZet-akn8Sds92DY7v2AbpcoPRg1F2PkIMQmePRwzI0WRM1AGzLCZ9tDY67xFsjbenIMDCBO67O-Kg_6z4Q?key=jmuWY49JvDMEQ_oV8ZOhEpb9" alt="" /></figure>
The JDST ETF: On the other side of the tracks, the Direxion Daily Junior Gold Miners bear fund has struggled to find its footing, losing more than 42% on a year-to-date basis.
<ul>
<li>A worrying element of JDST is its lack of traction. Presently, the inverse ETF is trading conspicuously below its 50 and 200 DMAs.</li>
<li>Since the first quarter of 2024, JDST has been stuck in a downward spiral. Without a line drawn in the sand, it's difficult to decipher where the bottom might be.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXei0qXez2nspyEFbpOBSbIPxRAwf7DvWL_dHpt47LmXUL60s3O3ODC2Fpad6YNqitJAhu8N8G0LaJ35kBrD0azZlNQW8GQZe6XC5UWcbbBWTFPGup7--arLLANLdxLjwl43Q6hG2g?key=jmuWY49JvDMEQ_oV8ZOhEpb9" alt="" /></figure>
Featured photo by <a href="https://pixabay.com/users/istara-200137/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=295936">istara</a> on <a href="https://pixabay.com/photos/gold-bullion-ing-gold-bullion-295936/">Pixabay</a>.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Short Ideas

Technicals

Commodities

ETFs

JDST

JNUG

Gold Fever Draws Eyes To Direxion's Junior Miners Bull And Bear Funds

WIIM

QFIN

Qifu Technology shares are trading higher after the company reported better-than-expected Q4 financial results.

Laidlaw &amp; Co. analyst Yale Jen initiates coverage on Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) with a Buy rating and announces Price Target of $19.

NVCT

Laidlaw & Co. Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $19

SRRK

Scholar Rock shares are trading higher after the company announced its phase 3 SAPPHIRE data results.

Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) reported quarterly losses of $(0.38) per share. This is a 82.49 percent increase over losses of $(2.17) per share from the same period last year. The company reported $91.93 million in sales this quarter. This is a 39.88 percent increase over sales of $65.72 million the same period last year.

SNDA

Sonida Senior Living Q4 2024 GAAP EPS $(0.38) Up From $(2.17) YoY, Sales $91.93M Up From $65.72M YoY

AGRO

Adecoagro Continues Discussions With Tether Investments On Tether's Proposal To Acquire Outstanding Common Shares Of Co. At $12.41/Share Through Tender Offer

CBAK Energy Technology Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) shares are trading lower premarket after it reported a&nbsp;FY24 revenue decline of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44350762/cbak-energy-reports-full-year-of-2024-unaudited-financial-results" rel="noreferrer noopener">13.61%&nbsp;year over year to&nbsp;$176.61&nbsp;million</a>.
Revenues were impacted by a decrease in sales from Hitrans, which is the company&#8217;s acquired raw materials production unit.
Battery business revenues rose 2.7% Y/Y to $136.59 million, owing to an increase of 84% Y/Y from batteries used in light electric vehicles. Net revenues from batteries used in electric vehicles declined 41.67% Y/Y.
Gross profit surged 31.68% Y/Y to $41.75 million. The gross margin stood at 23.7% vs. 15.5% a year ago. Gross profit from the battery business upped 36.33% Y/Y to $43.05 million in the year.
Net income attributable to shareholders was&nbsp;$11.79&nbsp;million, compared to a net loss of&nbsp;$2.45&nbsp;million in 2023. EPS rose to $0.13 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">from a loss of&nbsp;$(0.03)&nbsp;in 2023</a>.
As of December 31, 2024, cash and cash equivalents stood at&nbsp;$6.7 million.
Zhiguang Hu, the Chief Executive Officer, noted that the company&#8217;s results outperform many industry peers, including top Chinese battery manufacturers, despite challenges in the broader new energy sector. With demand for the Model 32140 exceeding supply, the company is actively scaling up production capacity.
Price Action: CBAT shares are up 2.35% to $0.83 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44347748/coinbase-apple-and-robinhood-are-among-top-large-cap-losers-last-week-mar-10-mar-14-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock.

Equities

CBAT

CBAK Energy Posts Profit in FY24, CEO Highlights Resilience In Battery Market

Summary of Financial Results for Full Year 2024 &nbsp;
Net loss was $8.2 million for the year ended December 31, 2024.
Research and development expenses were $3.8 million and $3.2 million for the years ended December 31, 2024 and 2023, respectively. The $0.6 million increase in research and development expenses was primarily due to increased expenses related to the registrational development program of GRI-0621.
General and administrative expenses were $4.5 million and $8.2 million for the years ended December 31, 2024 and 2023, respectively. The $3.7 million decrease was primarily due to a decrease of $3.4 million in accounting, legal, investment banking and other fees related to the merger with Vallon Pharmaceuticals, Inc. in April 2023.
As of December 31, 2024, the Company had cash and cash equivalents of approximately $5.0 million. Based on the Company's current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Reports As Of December 31, 2024, The Company Had Cash And Cash Equivalents Of ~$5M; Cash Runway Expected To Fund Operations Into Q2 2025, Including Interim Data Readout From GRI-0621

INCY

Incyte Corporation shares are trading lower after the company announced the results from its phase 3 STOP-HS clinical trial program of Povorcitinib for severe hidradenitis suppurativa.

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.59) by 20.34 percent. This is a 93.93 percent increase over losses of $(7.74) per share from the same period last year.

MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is trading around $84,400 on Monday morning, with macroeconomic events this week anticipated to set the tone for short-term price movement in the <a href="https://www.benzinga.com/money/bitcoin-price-prediction">weeks to come</a>.
What Happened: Crypto trader CrypNuevo on Sunday <a href="https://x.com/CrypNuevo/status/1901349895245619574">noted</a> that Bitcoin's one-week 50-day exponential moving average has held as support, prompting a bounce. 
If this level breaks, it could invalidate the bullish structure, similar to Q1 2022
The FOMC meeting on Wednesday is expected to inject high volatility into markets, particularly due to the dot plot release, which outlines future interest rate expectations.
Liquidation data suggests most liquidations are positioned to the upside. The main liquidity zone sits between $85,400 and $87,100—a likely target unless Bitcoin's short-term uptrend breaks. 
A move towards this range next week seems likely unless the short-term uptrend breaks. A quick dip below the trendline to trigger stop-losses is possible later in the week.
Coinglass data shows that Bitcoin liquidations in the past 24 hours hit $82.7 million, with $43.6 million in long liquidations. 
Bitcoin derivatives trading volume surged 85.4% in a single day, while options volume skyrocketed 190.5%.
Also Read: <a href="https://in.benzinga.com/25/03/44345006/arthur-hayes-predicts-bitcoin-surge-to-250000-by-year-end-says-current-downturn-is-clearing-out-deadwood-short-term-pain">Arthur Hayes Predicts Bitcoin Surge To $250,000 By Year-End, Says Current Downturn Is Clearing Out Deadwood: &#8216;Short-Term Pain&#8217;</a>
What's Next: Crypto enthusiast AlphaBTC <a href="https://x.com/mark_cullen/status/1901496108104196512">pointed</a> out that with the FOMC meeting this week, volatility will be high. 
Bitcoin appears to be targeting liquidity above the last two weekend highs, the CME gap and the mid-range. 
Whether it holds the mid-range post-FOMC will depend on how the data unfolds.
Trader Grey BTC <a href="https://x.com/greybtc/status/1901212858232218099">noted</a> that no rate cuts are expected, but traders should brace for volatility, as both Bitcoin and altcoins could see a price surge following the meeting.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44218404/raoul-pal-sees-bitcoin-solana-in-healing-stage-predicts-market-recovery-in-q2">Raoul Pal Sees Bitcoin, Solana In &#8216;Healing Stage&#8217;, Predicts Market Recovery In Q2</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Holds Steady At $84,000 As Wednesday FOMC Meeting Looms

DVLT

Datavault AI And NYIAX Partner To Integrate Datavault AI's Patented Information Data Exchange And Platform With NYIAX Blockchain Exchange Technology

<h3>Gainers</h3>
<ul>
<li>Emerson Radio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) stock moved upwards by 11.3% to $0.49 during Monday's pre-market session. The company's market cap stands at $10.3 million. </li>
<li>Zapp Electric Vehicles Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) stock increased by 10.46% to $0.89. The market value of their outstanding shares is at $5.8 million. </li>
<li>Raytech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) shares rose 9.01% to $1.33. The market value of their outstanding shares is at $23.4 million. </li>
<li>Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) shares moved upwards by 6.98% to $2.91. The market value of their outstanding shares is at $225.8 million. The company's, Q4 earnings came out today. </li>
<li>Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) stock moved upwards by 6.71% to $0.88. The company's market cap stands at $162.9 million. </li>
<li>Vacasa (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) stock moved upwards by 6.3% to $5.56. The market value of their outstanding shares is at $87.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares declined by 12.8% to $0.15 during Monday's pre-market session. The market value of their outstanding shares is at $4.7 million. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares fell 11.1% to $5.05. The company's market cap stands at $34.5 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock declined by 10.72% to $0.62. The market value of their outstanding shares is at $4.9 million. </li>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) stock decreased by 7.62% to $0.6. The market value of their outstanding shares is at $5.9 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares declined by 7.08% to $0.33. The market value of their outstanding shares is at $2.0 million. </li>
<li>PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) stock fell 6.56% to $1.14. The company's market cap stands at $106.8 million. The company's, Q4 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

LESL

LGCB

MTEN

PLBY

SBET

VCSA

ZAPP

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares increased by 107.6% to $5.19 during Monday's pre-market session. The company's market cap stands at $7.3 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock rose 39.89% to $1.08. The company's market cap stands at $1.0 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares rose 19.85% to $1.63. The company's market cap stands at $258.0 million. </li>
<li>Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) shares moved upwards by 19.23% to $3.1. The company's market cap stands at $340.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares increased by 17.47% to $4.1. The market value of their outstanding shares is at $19.8 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 14.63% to $0.35. The market value of their outstanding shares is at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares decreased by 25.0% to $2.55 during Monday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) stock decreased by 22.29% to $0.55. The market value of their outstanding shares is at $41.1 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) shares fell 14.9% to $57.75. The market value of their outstanding shares is at $11.1 billion. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock declined by 12.55% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) shares declined by 11.65% to $9.71. The company's market cap stands at $425.0 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares declined by 9.46% to $0.34. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ANNX

CAPS

CNTX

MAZE

PALI

REVB

SHPH

SNTI

12 Health Care Stocks Moving In Monday's Pre-Market Session

Press Releases

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Health Care

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

General

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Comments

BioCardia

Noticias

Últimas noticias sobre BioCardia (NASDAQ:BCDA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL